



ANATARA
L I F E S C I E N C E S

AGM

NOVEMBER 2020

ASX: ANR

Advancing gastrointestinal health



Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Key Investor Message

More than ever, the world is looking for safe and effective solutions to gut health.

The Anataro team is focussed on delivering evidence-based, commercially attractive solutions for gastrointestinal diseases in animals and humans.



Corporate Fast Facts



ASX ticker code

ANR

Share Price

\$0.175*

Market Capitalisation

\$11.7 million*

Ordinary Shares

66,783,270

Options

2,158,500

Performance Rights

780,985

Board of Directors:

Sue MacLeman

Dr Jane Ryan

Dr Tracie Ramsdale

Dr David Brookes

Management:

Steve Lydeamore, CEO

Dr Michael West, COO

Product Development

Advisory Board:

Prof Peter Gibson

Dr Rebecca Burgell

Dr Jakob Begun

Laureate Prof Nick Talley

Prof Jane Andrews

Prof Barry Campbell

Assoc Prof Simon Keely

Dr Tracey Brown

Achievements

Human health asset, GaRP:

- Intellectual property strengthened
- Achieved preclinical milestone
- Achieved clinical trial protocol milestone
- Clinical trial protocol modified to a 'virtual' clinical trial in IBS
- GMP manufacturing process completed allowing clinical manufacture
- Clinical trial in IBS submitted to ethics committee

Animal health assets:

- Poultry formulation (ANR-pf) developed
- In-feed piglet formulation (BONIFF) developed
- ANR-pf: challenge trial in poultry for subclinical and necrotic enteritis commenced
- BONIFF + Ridley's SMEC: Challenge trial in piglets for enterotoxigenic *Escheria coli* to commence in Q1, 2021

Our place in the microbiome treatment landscape

Identifying a specific bacterial strain, or group of strains, that is delivered alive to the patient's gut



Drugs that specifically target the bacteria that cause disease while leaving the rest of the gut microbiome intact



ANATARA
LIFESCIENCES



C3J Therapeutics



SECOND GENOME

Fecal microbiota treatment (FMT)



Bacteriophages



CRISPR/Cas9



Engineering bacteria to become drug factories directly within the human gut

Anaeropharma Science





ANATARA
LIFESCIENCES

Irritable Bowel Syndrome



IBS – Patient Impact

IBS is the most commonly diagnosed gastrointestinal condition and a significant cost burden on health care ².



Worldwide prevalence of IBS ¹

11.2%



45% of IBS-D patients agreed with the statement
*“I’m willing to try anything to help manage my IBS”*¹⁰



Individuals with IBS restrict their activities an average of

73 DAYS a year⁹



14% said they would risk a 1/1000 chance of death to live symptom-free¹⁰




47% of respondents with IBS-D stated that they had little or no ability to predict their symptoms on a daily basis¹⁰




Patients reported they would give up
25% of their remaining life (approx. 15 years)¹⁰

Attractive Target Market



3. Mintel's 2018 Digestive Health U.S. – July, 16; 4. Nutrition Business Journal (NBJ); 5. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-721; 6. Saunjo L. Yoon, Oliver Grundmann, Keore F. Smith & Sidney R. Mason (2018): Dietary Supplement and Complementary and Alternative Medicine Use Are Highly Prevalent in Patients with Gastrointestinal Disorders: Results from an Online Survey, Journal of Dietary Supplements; 7. O. Grundmann et al. Complementary Therapies in Medicine 41 (2018) 225–230; 8. Grundmann O, Yoon SL. Complementary and alternative medicines in irritable bowel syndrome: An integrative view. World J Gastroenterol 2014; 20(2): 346-362

Compelling Solution



Global consumer health market opportunity

US \$8 billion

Gastrointestinal supplements and OTC digestive remedies in USA alone ^{3,4}

Probiotic supplements



Align® (P&G) sales
(U.S.) 2018:
US\$171.9m⁹

Other GI supplements



Iberogast® (Bayer) sales
(Germany) 2018:
US\$145m⁹

OTC digestive supplements




Buscopan® (Sanofi) sales
(Global) 2018:
US\$220m¹⁰

(OTC only, excludes prescription sales)



GaRP
built on strong scientific
foundations

Anatara's Unique Complementary Medicine - How does it work?



GaRP has been shown to.....

- **Address the dysbiosis of the microbiome**
 - Inhibiting the attachment and invasion of pro-inflammatory bacteria by **>95%**
- **Reduce gut inflammation**
 - Reducing the production of pro-inflammatory proteins by **>85%**
 - Reducing colon inflammation and disrupted bowel habits by **2.5-fold** in mice
 - Potential to reduce immunosuppressive dosing in IBD when GaRP used as an adjunct to prescription immunosuppressants
- **Promote mucosal healing**
 - Upregulating the expression of mucin genes (MUC2 & MUC6) that are normally downregulated in both IBD and IBS
 - Increasing the expression of mucin genes by a factor of **5 to 7-fold** (MUC2 and MUC6 genes)



Grounded in scientific evidence



Successful Proof of Concept Studies (February & October 2019)
Demonstrated using industry-standard *in vitro* gut models

Next step: clinical trial

Description:

An adaptive, Randomized, Double-blinded, Placebo-controlled virtual clinical trial

Population:

Males and females 18-65 years of age with irritable bowel syndrome (IBS-SSS score of 175-300 and categorised as IBS-diarrhoea subtype on ROME IV criteria), two stages with interim analysis between stages

Endpoints

- ✓ Change in IBS-Severity Scoring System (IBS-SSS)
- ✓ Change in IBS quality of life points (IBS QoL)
- ✓ Stool consistency (IBS-D) using the Bristol Stool Form Scale
- ✓ IBS Adequate Relief (IBS-AR)
- ✓ Hospital Anxiety and Depression Scale (HAD)
- ✓ Catastrophizing questionnaire
- ✓ Safety markers
- ✓ Treatment-Related Adverse Events

Exploratory endpoints

- ✓ Plasma levels of specific inflammatory markers
- ✓ Alterations in gut microbiota with respect to diversity and function, and if this modification is correlated to a reduction in IBS-D symptoms
- ✓ Changes in Work Productivity and Activity Impairment Questionnaire



Future opportunities

Anatara has the potential to leverage and apply the proprietary know-how and IP created through the development of our GaRP complementary medicine into other gastrointestinal diseases that are caused by a disrupted microbiome, inflammation and mucosal damage such as:

- **Anxiety & Depression**
- **Functional Constipation**
- **Functional Diarrhoea**
- **Functional Dyspepsia**
- **Small Intestinal Bacterial Overgrowth (SIBO)**



Anticipated Company Milestones

	2018 H1	2018 H2	2019 H1	2019 H2	2020 H1	2020 H2	2021 H1	2021 H2
GaRP commercial feasibility	✓							
Patent Application filed		✓						
In vitro GaRP proof of concept								
- anti-inflammation			✓					
- anti-attachment			✓					
In vitro GaRP proof of concept								
- mucosal healing				✓				
GaRP animal study (IBD)				✓				
Human clinical study (IBS)								
- Pre-trial activities				✓				
- Commencement							★	
Partnering discussions								
- GaRP partnering deal							★	
Livestock challenge trials								
- Poultry							★ F	
- Piglets (in-feed)							S	F



ANATARA
LIFESCIENCES



Contact Anatara Lifesciences Ltd

Steven Lydeamore, Chief Executive Officer

+61 438 027 172

slydeamore@anatara.com

www.anataralifesciences.com

@AnataraANR



anatara-lifesciences-ltd

